Synthesis and characterization of basil seed mucilage coated Fe3O4 magnetic nanoparticles as a drug carrier for the controlled delivery of Cephalexin (cas 15686-71-2)
-
Add time:09/10/2019 Source:sciencedirect.com
A novel drug delivery system, loaded the drug cephalexin on the basil seed mucilage coated magnetic nanoparticles (Fe3O4@BSM-CPX) was prepared and characterized by means of X-ray diffraction (XRD), Furier Transform Infrared (FTIR), Field Emission Scanning Electron Microscope (FESEM), Vibrating Sample Magnetometer (VSM), Transmission Electron Microscopy (TEM), and Anti-bacterial, and Specific Surface (BET). By comparing the size of the uncoated nanoparticles (12 nm) and the size of the coated magnetite nanoparticles (6 nm), it was found that with the mucilage coating being put on the magnetite nanoparticles, the size of the nanoparticle cores has also decreased. The optimum pH results showed that the higher adsorption capacity occurs when cephalexin is cationic at pH 2.5 because the NH3+ group of cephalexin interacts better with negative functional groups of the basil seed mucilage. Disk Diffusion Anti-Bacterial test showed that the loading of CPX on the Fe3O4@BSM nanocarrier, not only does not have any negative effects on the structure and performance of the drug, but also increases the antibacterial properties of CPX. Furthermore, the in vitro release of Fe3O4@BSM-CPX nanocomposites showed an initial burst release in the first 18 h, followed by a more gradual and sustained release for 120 h.
We also recommend Trading Suppliers and Manufacturers of Cephalexin (cas 15686-71-2). Pls Click Website Link as below: cas 15686-71-2 suppliers
Prev:Cephalexin (cas 15686-71-2) nanoparticles: Synthesis, cytotoxicity and their synergistic antibacterial study in combination with silver nanoparticles
Next:Research ArticlesBioavailability of Orally Administered propiram (cas 15686-91-6) Fumarate in Humans) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Cephalexin (cas 15686-71-2) nanoparticles: Synthesis, cytotoxicity and their synergistic antibacterial study in combination with silver nanoparticles09/09/2019
- Z-scheme 2D/3D g-C3N4@ZnO with enhanced photocatalytic activity for Cephalexin (cas 15686-71-2) oxidation under solar light09/08/2019
- Effect of Cephalexin (cas 15686-71-2) after heterogeneous Fenton-like pretreatment on the performance of anaerobic granular sludge and activated sludge09/07/2019
- Star-shaped poly(ethylene oxide)‑block‑poly(caprolactone) conjugated silver nanoparticles: A colorimetric probe for Cephalexin (cas 15686-71-2) in environmental, biological and pharmaceutical samples09/06/2019
- Data ArticleData on Cephalexin (cas 15686-71-2) removal using powdered activated carbon (PPAC) derived from pomegranate peel09/05/2019
- Nanocomposite optosensor of dual quantum dot fluorescence probes for simultaneous detection of Cephalexin (cas 15686-71-2) and ceftriaxone09/04/2019
- Adsorption of tetracycline, ofloxacin and Cephalexin (cas 15686-71-2) antibiotics on boron nitride nanosheets from aqueous solution09/03/2019
- Determination of Cephalexin (cas 15686-71-2) residual level using ultra-high-performance liquid chromatography-tandem mass spectrometry: Residue depletion study in swine09/02/2019
- Preparation, physicochemical properties, in vitro evaluation and release behavior of Cephalexin (cas 15686-71-2)-loaded niosomes09/01/2019


